Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
NCT: NCT03145545 · AVAILABLE
Brief Summary
The primary objective of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia Institutional Review Board (IRB) approved protocols that utilize CliniMACs technology for T depletion.
Frequently Asked Questions
What is Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC?
Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC is a clinical trial registered under NCT03145545. Current status: AVAILABLE.
What is the status of NCT03145545?
The current status of NCT03145545 (Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC) is: AVAILABLE.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.